Treatment and Coronavirus (COVID-19)
is an infectious respiratory disease caused by SARS-CoV-2, previously
referred to as "2019 novel coronavirus."1
has not studied the use of abemaciclib in patients with COVID-19 nor
in patients at risk of contracting COVID-19.
Risk and Benefit Considerations
physicians should assess the patient’s individual benefit/risk
ratio considering the patient's signs and symptoms, prior medical
history, concomitant medications, and other individual factors when
making abemaciclib treatment decisions in the context of COVID-19.
Adverse reactions of abemaciclib to be considered in particular, in
the context of COVID-19, include ILD/pneumonitis and neutropenia (see
below for further information). Abemaciclib dose adjustments,
made at the physician’s discretion, should follow the label.
Supportive treatment should be provided as clinically indicated and
patients monitored appropriately. Drug interactions between
abemaciclib and potential COVID-19 treatments should be considered
and are described below.2
Warnings and Precautions
lung disease and/or pneumonitis was reported in patients receiving
abemaciclib. Monitor patients for pulmonary symptoms indicative of
ILD/pneumonitis and treat as medically appropriate.3
Symptoms may include hypoxia, cough, dyspnea, or interstitial
infiltrates on radiologic exams. Infectious, neoplastic, and other
causes for such symptoms should be excluded by means of appropriate
Based on the severity of ILD/pneumonitis, abemaciclib may require
Warnings and Precautions
was reported in patients receiving abemaciclib. 3
blood counts should be monitored prior to the start of Abemaciclib
therapy, every two weeks for the first two months, monthly for the
next two months, and as clinically indicated. 3
modification is recommended for patients who develop Grade 3 or
or chloroquine are not expected to have a clinically relevant effect
on abemaciclib exposure.2
favipiravir or azithromycin are not expected to have a clinically
relevant effect on abemaciclib exposure. 2
combination of lopinavir/ritonavir is a strong CYP3A inhibitor.2 With
concomitant use of strong CYP3A inhibitors other than ketoconazole,
in patients with recommended starting doses of 200 mg twice daily or
150 mg twice daily, reduce the abemaciclib dose to 100 mg twice
daily. In patients who have had a dose reduction to 100 mg twice
daily due to adverse reactions, further reduce the abemaciclib dose
to 50 mg twice daily.4
the most current information regarding COVID-19, please refer to the
Naming the coronavirus disease (COVID-19) and the virus that causes
it. World Health Organization. Accessed March 17, 2020.
Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Verzenios [summary of product characteristics]. Eli Lilly Nederland
B.V., The Netherlands.
Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company;
Coronavirus disease (COVID-19) outbreak. World Health Organization
Europe. Accessed March 20, 2020.
COVID-19. European Centre for Disease Prevention and Control.
Accessed March 20, 2020.
European Society for Medical Oncology. Accessed March 23th.
[NICE] National Institute for Health and Care Excellence.
Coronavirus (COVID-19). Available from:
Accessed 25 March 2020.
= coronavirus disease 2019
= interstitial lung disease
= Eli Lilly and Company
= European Centre for Disease Prevention and Control
= European Society for Medical Oncology
WHO = World Health Organization (European regional office)
= severe acute respiratory syndrome coronavirus 2
= World Health Organization
medicinal product is subject to additional monitoring. This will
allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse reactions.